VC and Investment
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Today's issue
Refine Search
Biotechnology
San Francisco, USA-based biotech start-up Kivu Bioscience has announced the closing of a $92 million Series A financing round led by Novo Holdings, which as of year-end 2011123 had total assets of 149 billion euros ($161 billion). 28 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Biostar Pharmaceuticals has announced its upcoming initial public offering (IPO) on the Hong Kong Stock Exchange, aiming to raise funds to advance its growing oncology pipeline and support its global expansion efforts. 25 October 2024
Biotechnology
Belgian biotech Agomab Therapeutics today announced a $89 million (82.1 million euros) Series D financing round, with participation from new investors Sanofi and Invus 25 October 2024
Pharmaceutical
Alpha-9 Oncology, a Canadian radiopharmaceutical company, has raised $175 million in an oversubscribed series C financing round led by Lightspeed Venture Partners and Ascenta Capital. 24 October 2024
Biotechnology
US clinical-stage biotech AvenCell Therapeutics announced that it has raised $112 million in Series B financing, which was led by global life sciences investor Novo Holdings. 23 October 2024
Biotechnology
Boston, USA-based Seaport Therapeutics has announced the closing of an oversubscribed $225 million Series B financing round, adding to the $100 million it pulled in along with its launch in April. 21 October 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Biotechnology
LaNova Medicines, a Shanghai-based biopharma company, has announced that it has secured 3 billion yuan ($41 million) in its series C funding round. 18 October 2024
Biotechnology
California, USA-based biotech Terray Therapeutics, yesterday announced the closing of an oversubscribed Series B funding of $120 million. 18 October 2024
Pharmaceutical
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
Pharmaceutical
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
Pharmaceutical
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
Pharmaceutical
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Biotechnology
In Cambridge, UK, the protein specialist Nuclera has raised $75 million in a funding round led by Elevage Medical Technologies and backed by Patient Square Capital. 16 October 2024
Biotechnology
Tolerance Bio has announced the closing of its oversubscribed $17.2 million seed financing round, led by Columbus Venture Partners. 16 October 2024
Biotechnology
In Hong Kong, Akeso Biopharma has successfully raised $250 million through a share placement, marking its second major fundraising effort of 2024. 15 October 2024
Pharmaceutical
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
Biotechnology
Turnstone Biologics has announced a major restructuring of its operations, cutting its workforce by approximately 60%. 14 October 2024
Biotechnology
Boston, USA-based Upstream Bio, a biotech developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, has made an impressive start to life as a public-listed company.00000 14 October 2024
Pharmaceutical
Despite an initial blip, shares in AstraZeneca have climbed by 8% since the Anglo-Swedish pharma major announced its 2016 results last week, reaching £46.18 ($57.48) by Friday lunchtime. 10 February 2017
Pharmaceutical
Italian drugmaker Recordati has not only announced an increase in revenue for 2016 of more than 10%, but has also predicted that it will rise by a further 26% by 2019. 9 February 2017
Pharmaceutical
GlaxoSmithKline has delivered 2016 sales growth of 6% and improved cash flow in figures boosted by the Brexit-hit pound, but the UK pharma major accepts that generic competition to a big-selling respiratory drug could hit its revenue in 2017. 8 February 2017
Pharmaceutical
The upbeat mood at Danish CNS specialist Lundbeck over its impressive 2016 financial results will be countered by the market reaction to news of its failure in an Alzheimer’s program. 8 February 2017
Biotechnology
US biopharma Cytokinetics has agreed to sell a portion of the potential royalty due from US biotech Amgen on worldwide sales of an investigatory heart failure drug to private equity firm Royalty Pharma. 2 February 2017
Pharmaceutical
Merck & Co’s 2016 financial results offer further evidence of why the company is the envy of the industry due to its ownership of the immuno-oncology drug Keytruda (pembrolizumab). 2 February 2017
Pharmaceutical
Shares in AstraZeneca fell around 1.5% this morning as the company provided cautious 2017 guidance as part of its full year and fourth quarter financial results statement. 2 February 2017
Pharmaceutical
US pharma giant Pfizer missed analysts’ estimates with its forecast for revenue for 2017 as it presented a set of results which showed the increasing impact of competition and the company’s focus on mergers and acquisitions (M&A). 31 January 2017
Biotechnology
Mindful that the next two years will be massively important for the company and how closely pharma will be watching its progress, it is not surprising that Realm Therapeutics has been keen to let the world know its plans for 2017. 31 January 2017
Pharmaceutical
US pharma major Bristol-Myers Squibb might have been able to point to a 17% increase in its 2016 sales compared to 2015, but it share price and outlook for 2017 tell a different story of the year it has had. 26 January 2017
Generics
Beximco Pharmaceuticals has entered into a collaboration with Malaysia’s BioCare Manufacturing, in what will be the Bangladeshi generics firm’s first overseas manufacturing deal. 25 January 2017
Pharmaceutical
Slowing growth in pharmaceuticals has been blamed for a drop in the share price of Johnson & Johnson (NYSE: JNJ) after the world’s biggest healthcare business published its fourth quarter and full 2016 financial results. 24 January 2017
Biotechnology
In an expert view piece, Dr Oded Ben-Joseph and Dr Shawn Manning, from investment bank Outcome Capital, advise on how life sciences companies can curtail risk by allocating time and money in a capital-efficient manner. 19 January 2017
Generics
Israeli generics giant Teva Pharmaceutical Industries felt the force of a Friday battering in the stock market after reducing its revenue forecast for 2017 by more than $1 billion. 6 January 2017
Biotechnology
The clear-up looks to have begun at Alexion Pharmaceuticals after an alarming few months. 5 January 2017
Pharmaceutical
US pharma giant Merck & Co is now managing its own vaccines portfolio across Europe. 4 January 2017
Biotechnology
The board of directors of US biotech Biogen has approved the spin-off of its hemophilia business, which will be known as Bioverativ Inc. 21 December 2016
Biotechnology
USA-based RNAi therapeutics company Alnylam Pharmaceuticals jumped by nearly 3% to $44.39 in Friday’s trading after presenting its 2017 pipeline goals. 19 December 2016
Pharmaceutical
Shares in US pharma major Eli Lilly were up by 4.5%, at $70.71, by lunchtime on Thursday following the company’s announcement of its 2017 financial guidance and outlook for the next decade. 15 December 2016
Pharmaceutical
Projected returns on investment in research and development (R&D) for the top 12 pharma companies have fallen to their lowest level in six years, reveals a new report from Deloitte’s Centre for Health Solutions. 14 December 2016
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze